In recent years, China has made it easier for international drugmakers to bring their products here. So how are top pharmaceutical companies planning to capitalize on these new opportunities? CGTN's Cui Hui'ao talked to several CEOs at the China International Import Expo.

At China's first ever International Import Expo, European drugmaker AstraZeneca is launching 7 new drugs. One of them treats renal amenia, a life-threatening disease. It's a first for China.

LEON WANG, EXECUTIVE VP ASTRAZENECA "This would be the first new drug that was first approved in China and then get approval in Japan and the U.S."

In China now for 25 years, AstraZeneca was one of the first international companies to benefit from the nation's opening up. Now, with the government simplifying registration and approval procedures, launching drugs in China is no longer as challenging as before. Similar companies are also taking advantage of this, like U.S. giant Johnson & Johnson. Their latest products help patients with diseases like leukemia and schizophrenia.

VLADIMIR MAKATSARIA, CHAIRMAN JOHNSON & JOHNSON CHINA "For us the most important thing is how we make sure healthcare systems help innovative products to come to the market faster and be rewarded faster."

CUI HUI'AO NATIONAL EXHIBITION AND CONVENTION CENTER, SHANGHAI "As the world's second-largest pharmaceutical consumer market after the US, China's continued opening up has prompted many multinational medical companies to up their ante across the country and further explore its market."

Effective May 1st of this year, China eliminated tariffs for all cancer drugs. It's seen as a policy that will benefit Chinese patients and boost global pharmaceutical companies.

XIAOJING CHEN, VP NOVARTIS GROUP (CHINA) "China's adherence to free trade and creating a better business environment will bring great confidence and impetus to Novartis's pursuits in China."

In the next ten years, the market for China's health industry is expected to exceed 10 trillion yuan. And the country plans to import products and services worth over 10 trillion U.S. dollars. Goals made possible thanks to an open market. Cui Hui'ao, CGTN, Shanghai.